Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 8291-8300 of 8851

  • Results filtered:
  • Locations: Rochester, MN
Edit search filters
  1. Automated Non-Invasive Arterial Pressure Device in Normals and in Patients with Peripheral Arterial Disease

    Rochester, MN

  2. Pharmacogenomics Education within Nurse Anesthesia Programs and Implications for the Anesthesia Provider

    Rochester, MN

  3. A Study to Identify Discomforts Among Intensive Care Unit Patients

    Rochester, MN

  4. A Study to Evaluate Progenitor Cells for Patients with Degenerative Lung Disease

    Rochester, MN

  5. Long-term Outcomes of a Clinical Ketamine Service for Treatment-resistant Depression

    Rochester, MN

  6. Identify Exomic Alterations that Contribute to the Development of Liver Disease

    Rochester, MN

  7. Challenges in Medication Coverage in Pediatric Epilepsy

    Rochester, MN

  8. A Study to Evaluate a Personal Assistant Device and Accessory Technology for Epilepsy (Enrolling by Invitation Only)

    Rochester, MN

  9. Relapse Prediction Following Discontinuation of Tocilizumab In Giant Cell Arteritis

    Rochester, MN

  10. Abnormal Glycosylation on the Hypothalamic-Pituitary Adrenal and -Gonadal Axes and Bone Health in Patients with Congenital Disorders of Glycosylation

    Rochester, MN

.

Mayo Clinic Footer